Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis

References

• Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–1619.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR. Budesonide multi-matrix for the treatment of patients with ulcerative colitis. Dig Dis Sci. 2016;61:358–370.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Peyrin-Biroulet L, Sturm A, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - multicenter European cohort study. Dig Liver Dis. 2016;48:592–600.
   PubMedGoogle Scholar
• Hiraoka S, Kato J, Nakarai A, et al. Consecutive measurements by faecal immunochemical test in quiescent ulcerative colitis patients can detect clinical relapse. J Crohns Colitis. 2016;10:687–694.
   PubMed Web of Science ®Google Scholar
• Vilela EG, Torres HO, Martins FP, et al. Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J. Gastroenterol. 2012;18:872–881.
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Colombel JF, Filippi J, et al.. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150: 380–388.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Friedman S. Tofacitinib for ulcerative colitis - a promising step forward. N Engl J Med. 2017;376:1792–1793.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. J Crohns Colitis. 2015;9:147–155.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587–1590.
   PubMed Web of Science ®Google Scholar
• Yao P, Cui M, Wang H, et al. Quantitative analysis of intestinal flora of Uygur and Han Ethnic Chinese patients with ulcerative colitis. Gastroenterol Res Pract. 2016;2016:9186232.
   PubMed Web of Science ®Google Scholar
• Hilmi I, Jaya F, Chua A, et al. A first study on the incidence and prevalence of IBD in Malaysia–results from the Kinta Valley IBD Epidemiology Study. J Crohns Colitis. 2015;9:404–409.
   PubMed Web of Science ®Google Scholar
• Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol. 2002;8:158–161.
   PubMed Web of Science ®Google Scholar
• Salupere R. Inflammatory bowel disease in Estonia: a prospective epidemiologic study 1993–1998. World J Gastroenterol. 2001;7:387–388.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Ye BD, Choi H, Hong M, et al. Identification of ten additional susceptibility loci for ulcerative colitis through immunochip analysis in Koreans. Inflamm Bowel Dis. 2016;22:13–19.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
   PubMed Web of Science ®Google Scholar
• Gupta A, Thelma BK. Identification of critical variants within SLC44A4, an ulcerative colitis susceptibility gene identified in a GWAS in north Indians. Genes Immun. 2016;17:105–109.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553–1563.
   PubMed Web of Science ®Google Scholar
• Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27:1266–1280.
   PubMed Web of Science ®Google Scholar
• Asher GN, Spelman K. Clinical utility of curcumin extract. Altern Ther Health Med. 2013;19:20–22.
   PubMed Web of Science ®Google Scholar
• Zlotogorski A, Dayan A, Dayan D, et al. Nutraceuticals as new treatment approaches for oral cancer–I: Curcumin. Oral Oncol. 2013;49:187–191.
   PubMed Web of Science ®Google Scholar
• Hu S, Maiti P, Ma Q, et al. Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother. 2015;15:629–637.
   PubMed Web of Science ®Google Scholar
• Devassy JG, Nwachukwu ID, Jones PJ. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev. 2015;73:155–165.
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh NP, Busbee B, et al. Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 2012;31:66–84.
   PubMed Web of Science ®Google Scholar
• Vecchi Brumatti L, Marcuzzi A, Tricarico PM, et al. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules. 2014;19:21127–21153.
   PubMed Web of Science ®Google Scholar
• Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014;46:2–18.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577–594.
   PubMed Web of Science ®Google Scholar
• Jump RL, Levine AD. Mechanisms of natural tolerance in the intestine: implications for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2004;10:462–478.
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289–298.
   PubMed Web of Science ®Google Scholar
• Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol. 2010;16:4145–4151.
   PubMed Web of Science ®Google Scholar
• Wiese DM, Horst SN, Brown CT, et al. Serum fatty acids are correlated with inflammatory cytokines in ulcerative colitis. PLoS One. 2016;11:e0156387.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998;42:477–484.
   PubMed Web of Science ®Google Scholar
• Sreedhar R, Arumugam S, Thandavarayan RA, et al. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease. Drug Discov Today. 2016;21:843–849.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Pettersson S, Meyer Zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998–1004.
   PubMed Web of Science ®Google Scholar
• Taylor RA, Leonard MC. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev. 2011;16:152–156.
   PubMedGoogle Scholar
• Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999;163:3474–3483.
   PubMed Web of Science ®Google Scholar
• Stucchi A, Reed K, O’Brien M, et al. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis. 2006;12:581–587.
   PubMed Web of Science ®Google Scholar
• Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996;16:144–150.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42:880–888.
   PubMed Web of Science ®Google Scholar
• Shi XZ, Lindholm PF, Sarna SK. NF-kappa B activation by oxidative stress and inflammation suppresses contractility in colonic circular smooth muscle cells. Gastroenterology. 2003;124:1369–1380.
   PubMed Web of Science ®Google Scholar
• Bonizzi G, Karin M. The two NF-kappa B activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280–288.
   PubMed Web of Science ®Google Scholar
• Greten FR, Arkan MC, Bollrath J, et al. NF-kappa B is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKK beta. Cell. 2007;130:918–931.
   PubMed Web of Science ®Google Scholar
• Atreya I, Atreya R, Neurath MF. NF-kappa B in inflammatory bowel disease. J Intern Med. 2008;263:591–596.
   PubMed Web of Science ®Google Scholar
• Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol. 2002;2:725–734.
   PubMed Web of Science ®Google Scholar
• Li XH, Fang X, Gaynor RB. Role of IKK gamma/NEMO in assembly of the Ikappa B kinase complex. J Biol Chem. 2001;276:4494–4500.
   PubMed Web of Science ®Google Scholar
• Zandi E, Rothwarf DM, Delhase M, et al. The Ikappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for Ikappa B phosphorylation and NF-kappa B activation. Cell. 1997;91:243–252.
   PubMed Web of Science ®Google Scholar
• Rogler G, Brand K, Vogl D, et al. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998;115:357–369.
   PubMed Web of Science ®Google Scholar
• Gelbmann CM, Leeb SN, Vogl D, et al. Inducible CD40 expression mediates NF kappa B activation and cytokine secretion in human colonic fibroblasts. Gut. 2003;52:1448–1456.
   PubMed Web of Science ®Google Scholar
• Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008;75:787–809.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol. 2015;83:111–124.
   PubMed Web of Science ®Google Scholar
• Lee KH. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod. 2010;73:500–516.
   PubMed Web of Science ®Google Scholar
• Martin DA, Bolling BW. A review of the efficacy of dietary polyphenols in experimental models of inflammatory bowel diseases. Food Funct. 2015;6:1773–1786.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Coco R, Memvanga PB, et al. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm. 2014;473:203–212.
   PubMed Web of Science ®Google Scholar
• Ukil A, Maity S, Karmakar S, et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003;139: 209–218.
   PubMed Web of Science ®Google Scholar
• Midura-Kiela MT, Radhakrishnan VM, Larmonier CB, et al. Curcumin inhibits interferon-gamma signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2012;302:G85–G96.
   PubMed Web of Science ®Google Scholar
• Mouzaoui S, Rahim I, Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-alpha-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol. 2012;12:302–311.
   PubMed Web of Science ®Google Scholar
• Baliga MS, Joseph N, Venkataranganna MV, et al. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food Funct. 2012;3:1109–1117.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology. 2002;123:1912–1922.
   PubMed Web of Science ®Google Scholar
• Zhang M, Deng C, Zheng J, et al. Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int. Immunopharmacol. 2006;6:1233–1242.
   PubMed Web of Science ®Google Scholar
• Arafa HM, Hemeida RA, El-Bahrawy AI, et al. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol. 2009;47:1311–1317.
   PubMed Web of Science ®Google Scholar
• Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol. 2007;7:333–342.
   PubMed Web of Science ®Google Scholar
• Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med. 2007;19:469–474.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28:1937–1955.
   PubMed Web of Science ®Google Scholar
• Ung VY, Foshaug RR, MacFarlane SM, et al. Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Dig Dis Sci. 2010;55:1272–1277.
   PubMed Web of Science ®Google Scholar
• Buhrmann C, Mobasheri A, Busch F, et al. Curcumin modulates nuclear factor kappa B (NF-kappa B)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2011;286:28556–28566.
   PubMed Web of Science ®Google Scholar
• Murakami A, Furukawa I, Miyamoto S, et al. Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis. BioFactors. 2013;39:221–232.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J . 2013;15:195–218.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey. J Gastroenterol Hepatol. 2010;25:183–193.
   PubMed Web of Science ®Google Scholar
• Singla V, Pratap Mouli V, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014;8:208–214.
   PubMed Web of Science ®Google Scholar
• Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116:602–609.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.
   PubMed Web of Science ®Google Scholar
• Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des. 2009;15:2087–2094.
   PubMed Web of Science ®Google Scholar
• Faubion Jr WA, Loftus Jr EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–649.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Gordon GL, Zakko S, et al. Long-term benefit of mesalamine granules for patients who achieved corticosteroid-induced ulcerative colitis remission. Dig Dis Sci. 2016;61:221–229.
   PubMed Web of Science ®Google Scholar
• Dulbecco P, Savarino V. Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol. 2013;19:9256–9270.
   PubMed Web of Science ®Google Scholar
• Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001;55:716–720.
   PubMed Web of Science ®Google Scholar
• Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502–1506.
   PubMed Web of Science ®Google Scholar
• Marin-Jimenez I, Nos P, Domenech E, et al. Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study. Am J Gastroenterol. 2016;111:261–268.
   PubMed Web of Science ®Google Scholar
• Ikeya K, Hanai H, Sugimoto K, et al. The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the mayo endoscopic score. J Crohns Colitis. 2016;10:286–295.
   PubMed Web of Science ®Google Scholar
• Khan I, Samson SE, Grover AK. Antioxidant supplements and gastrointestinal diseases: a critical appraisal. Med Princ Pract. 2017;26:201–217.
   PubMed Web of Science ®Google Scholar
• Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1444–1449.
   PubMed Web of Science ®Google Scholar
• Xiao B, Si X, Zhang M, et al. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloids Surf B Biointerfaces. 2015;135:379–385.
   PubMed Web of Science ®Google Scholar
• Kumar S, Ahuja V, Sankar MJ, et al. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD008424.
   PubMedGoogle Scholar
• Suskind DL, Wahbeh G, Burpee T, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 2013;56:277–279.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhai W, Jiang Q, et al. Curcumin-piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int J Pharm. 2015;490:22–31.
   PubMed Web of Science ®Google Scholar
• Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191–2193.
   PubMed Web of Science ®Google Scholar
• Adapala N, Chan MM. Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model. Lab Invest. 2008;88:1329–1339.
   PubMed Web of Science ®Google Scholar
• Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther. 1999;13:245–249.
   PubMed Web of Science ®Google Scholar
• Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids. 1995;52:223–227.
   PubMed Web of Science ®Google Scholar
• Srivastava R, Dikshit M, Srimal RC, et al. Anti-thrombotic effect of curcumin. Thromb Res. 1985;40:413–417.
   PubMed Web of Science ®Google Scholar